Chiara Monfrini

Chiara Monfrini

Auto-generated profile, based on publicly available information

Chiara Monfrini

Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CMChiara Monfrini
Chiara Monfrini
FSFederico Stella
Federico Stella
VAVanessa Aragona
Vanessa Aragona
MMMartina Magni
Martina Magni
SLSilva Ljevar
Silva Ljevar
CCCristiana Carniti
Cristiana Carniti
Purpose: In clinical trials, the expansion and persistence of chimeric antigen receptor (CAR) T cells correlate with therapeutic efficacy. However, properties of CAR T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR T bag content has never been investigated in a real-life setting. Experimental Design: Residual cells obtained after washing 61 anti-CD19 CAR T product bags were analyzed to identify tisagenlecleucel/Tisa-cel and axicabtagene ciloleucel/Axi-cel phenotypic features associated with postinfusion CAR T-cell in vivo expansion and with response and survival. Results: While Tisa-cel was characterized by a significant enrichment in CAR+CD4+ T cells with central memory (P < 0.005) and effector (P < 0.005) phenotypes and lower rates of CAR+CD8+ with effector memory (P < 0.005) and naïve-like (P < 0.05) phenotypes as compared with Axi-cel, the two products displayed similar expansion kinetics. In vivo CAR T-cell expansion was influenced by the presence of CAR T with a CD8+ T central memory signature (P < 0.005) in both Tisa-cel and Axi-cel infusion products and was positively associated with response and progression-free survival (P < 0.05). Conclusions: Our data indicate that despite the great heterogeneity of Tisa-cel and Axi-cel products, the differentiation status of the infused cells mediates CAR T-cell in vivo proliferation that is necessary for antitumor response.

25 April 2022 in British Journal of Haematology
Verified
Journal Article
Open access
ECEleonora Calabretta
Eleonora Calabretta
AGAnna Guidetti
Anna Guidetti
FRFrancesca Ricci
Francesca Ricci
MTMartina Di Trani
Martina Di Trani
CMChiara Monfrini
Chiara Monfrini
Carmelo Carlo-StellaCarmelo Carlo-Stella
Carmelo Carlo-Stella
Summary: Checkpoint inhibitors (CPIs) are routinely employed in relapsed/refractory classical Hodgkin lymphoma. Nonetheless, persistent long‐term responses are uncommon, and one‐third of patients are refractory. Several reports have suggested that treatment with CPIs may re‐sensitize patients to chemotherapy, however there is no consensus on the optimal chemotherapy regimen and subsequent consolidation strategy. In this retrospective study we analysed the response to rechallenge with chemotherapy after CPI failure. Furthermore, we exploratively characterized the clonal evolution profile of a small sample of patients (n = 5) by employing the CALDER approach. Among the 28 patients included in the study, 17 (71%) were primary refractory and 26 (92%) were refractory to the last chemotherapy prior to CPIs. Following rechallenge with chemotherapy, response was recorded in 23 (82%) patients experiencing complete remission and 3 (11%) patients experiencing partial remission. The tumour evolution of the patients inferred by CALDER seemingly occurred prior to the first cycle of therapy and was characterized either by linear or branching evolution patterns. Twenty‐five patients proceeded to allogeneic stem cell transplantation. At a median follow‐up of 21 months, median PFS and OS were not reached. In conclusion, patients who fail CPIs can be effectively rescued by salvage chemotherapy and bridged to allo‐SCT/auto‐SCT.

31 March 2023
Verified
Other
Open access
CMChiara Monfrini
Chiara Monfrini
FSFederico Stella
Federico Stella
VAVanessa Aragona
Vanessa Aragona
MMMartina Magni
Martina Magni
SLSilva Ljevar
Silva Ljevar
CCCristiana Carniti
Cristiana Carniti
Supplementary Data from Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma

31 March 2023
Verified
Other
Open access
CMChiara Monfrini
Chiara Monfrini
FSFederico Stella
Federico Stella
VAVanessa Aragona
Vanessa Aragona
MMMartina Magni
Martina Magni
SLSilva Ljevar
Silva Ljevar
CCCristiana Carniti
Cristiana Carniti
Supplementary Data from Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma

31 March 2023
Verified
Other
Open access
CMChiara Monfrini
Chiara Monfrini
FSFederico Stella
Federico Stella
VAVanessa Aragona
Vanessa Aragona
MMMartina Magni
Martina Magni
SLSilva Ljevar
Silva Ljevar
CCCristiana Carniti
Cristiana Carniti
Purpose:In clinical trials, the expansion and persistence of chimeric antigen receptor (CAR) T cells correlate with therapeutic efficacy. However, properties of CAR T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR T bag content has never been investigated in a real-life setting.Experimental Design:Residual cells obtained after washing 61 anti-CD19 CAR T product bags were analyzed to identify tisagenlecleucel/Tisa-cel and axicabtagene ciloleucel/Axi-cel phenotypic features associated with postinfusion CAR T-cell in vivo expansion and with response and survival.Results:While Tisa-cel was characterized by a significant enrichment in CAR+CD4+ T cells with central memory (P < 0.005) and effector (P < 0.005) phenotypes and lower rates of CAR+CD8+ with effector memory (P < 0.005) and naïve-like (P < 0.05) phenotypes as compared with Axi-cel, the two products displayed similar expansion kinetics. In vivo CAR T-cell expansion was influenced by the presence of CAR T with a CD8+ T central memory signature (P < 0.005) in both Tisa-cel and Axi-cel infusion products and was positively associated with response and progression-free survival (P < 0.05).Conclusions:Our data indicate that despite the great heterogeneity of Tisa-cel and Axi-cel products, the differentiation status of the infused cells mediates CAR T-cell in vivo proliferation that is necessary for antitumor response.

31 March 2023
Verified
Other
Open access
CMChiara Monfrini
Chiara Monfrini
FSFederico Stella
Federico Stella
VAVanessa Aragona
Vanessa Aragona
MMMartina Magni
Martina Magni
SLSilva Ljevar
Silva Ljevar
CCCristiana Carniti
Cristiana Carniti
Purpose:In clinical trials, the expansion and persistence of chimeric antigen receptor (CAR) T cells correlate with therapeutic efficacy. However, properties of CAR T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR T bag content has never been investigated in a real-life setting.Experimental Design:Residual cells obtained after washing 61 anti-CD19 CAR T product bags were analyzed to identify tisagenlecleucel/Tisa-cel and axicabtagene ciloleucel/Axi-cel phenotypic features associated with postinfusion CAR T-cell in vivo expansion and with response and survival.Results:While Tisa-cel was characterized by a significant enrichment in CAR+CD4+ T cells with central memory (P < 0.005) and effector (P < 0.005) phenotypes and lower rates of CAR+CD8+ with effector memory (P < 0.005) and naïve-like (P < 0.05) phenotypes as compared with Axi-cel, the two products displayed similar expansion kinetics. In vivo CAR T-cell expansion was influenced by the presence of CAR T with a CD8+ T central memory signature (P < 0.005) in both Tisa-cel and Axi-cel infusion products and was positively associated with response and progression-free survival (P < 0.05).Conclusions:Our data indicate that despite the great heterogeneity of Tisa-cel and Axi-cel products, the differentiation status of the infused cells mediates CAR T-cell in vivo proliferation that is necessary for antitumor response.